Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic ...

The company states: “Datroway, or Dato-DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast ...

The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a treatment for previously treated HR+/HER2- breast cancer, a few weeks after its ...

It is the first global approval for the drug – which has been cleared under the Datroway brand name – with Japan's Ministry of Health, Labour and Welfare (MHLW) backing its use for patients ...

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39 ...

(Alliance News) - AstraZeneca PLC on Monday said Datroway has been approved in the US for patients with a type of breast cancer. The Cambridge-based pharmaceuticals firm explained the final ...

(Sharecast News) - AstraZeneca announced on Monday that it has secured approval from the US Food and Drug Administration, alongside Daiichi Sankyo, for 'Datroway', or datopotamab deruxtecan ...

Vandana Singh FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies ...

Vandana Singh FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies ...